Business Context and Reporting Period
This Form 8-K, filed on April 19, 2021, reports the completion of OncoCyte Corporation's acquisition of Chronix Biomedical, Inc. ("Chronix") on April 15, 2021. Chronix, a privately-held molecular diagnostics company with operations in the U.S. and Germany, develops blood tests for cancer treatment and organ transplantation. The acquisition grants OncoCyte access to Chronix's TheraSure™ CNI Monitor for cancer and TheraSure™ Transplant Monitor for organ rejection detection.
Key Financial Metrics and Transaction Terms
The filing details the consideration and liabilities associated with the merger rather than standard operating financials for a reporting period.
- Closing Consideration: Approximately $5.75 million in total value delivered on the Closing Date, consisting of:
- Stock: 591,000 shares of OncoCyte common stock (valued at approx. $1.13 million to stockholders and $1.87 million to pay liabilities based on a $5.09 share price).
- Cash: $4.25 million (approx. $3.88 million to pay liabilities and $0.37 million for fractional shares).
- Assumed Liabilities: OncoCyte assumed $2.5 million of Chronix liabilities payable in installments through July 2022.
- Excess Liabilities: Chronix had approx. $4.6 million in excess liabilities as of the Closing Date, which may be set off against future milestone payments.
- Future Consideration: Up to $14 million in milestones (cash or stock) and earnouts of up to 15% of net collections for specified tests (5-10 years) and up to 75% of net collections from patent sales/licenses in transplantation medicine (7 years).
Material Changes
The primary material change is the consolidation of Chronix as a wholly-owned subsidiary of OncoCyte. Additionally, the maximum number of shares issuable under the Merger Agreement was reduced from 15,724,000 to 7,861,000, and the mix of cash and stock consideration was reallocated compared to prior announcements. OncoCyte's common stock trading symbol changed from NYSE American to The Nasdaq Global Market ("OCX") effective March 8, 2021.
Outlook, Risks, and Contingencies
Outlook: Chronix expects to utilize its German laboratory network to accelerate the commercial launch of OncoCyte's DetermaRx™ product in the European Union.
Risks and Contingencies: The filing includes extensive forward-looking statement disclaimers. Key risks include:
- Failure to realize anticipated benefits or synergies.
- Unexpected expenditures or liabilities exceeding the $8.25 million cap.
- Difficulties in integrating business practices, accounting policies, and personnel.
- Inability to maintain laboratory accreditation or certification.
- Unforeseen adverse effects on operating results due to inaccurate performance forecasting.
Unusual Items: The issuance of 591,000 shares was unregistered, relying on exemptions for accredited investors and non-U.S. persons. OncoCyte intends to file a registration statement for the resale of these shares within 90 days.
Investor Verification Checklist
- Verify the final financial statements of Chronix, which OncoCyte intends to provide in an amended filing.
- Review the pro forma financial information to be filed to understand the combined entity's financial position.
- Monitor the achievement of the $14 million milestone targets and the specific net collection thresholds for earnouts.
- Confirm the status of the registration statement for the resale of the 591,000 unregistered shares issued to Chronix stockholders.
- Assess the integration progress of Chronix's German operations with OncoCyte's existing business.